Berthold H K, Sudhop T, von Bergmann K
Department of Clinical Pharmacology, University of Bonn, Germany.
JAMA. 1998 Jun 17;279(23):1900-2. doi: 10.1001/jama.279.23.1900.
Garlic-containing drugs have been used in the treatment of hypercholesterolemia even though their efficacy is not generally established. Little is known about the mechanisms of action of the possible effects on cholesterol in humans.
To estimate the hypocholesterolemic effect of garlic oil and to investigate the possible mechanism of action.
Double-blind, randomized, placebo-controlled trial.
Outpatient lipid clinic.
We investigated 25 patients (mean age, 58 years) with moderate hypercholesterolemia.
Steam-distilled garlic oil preparation (5 mg twice a day) vs placebo each for 12 weeks with wash-out periods of 4 weeks.
Serum lipoprotein concentrations, cholesterol absorption, and cholesterol synthesis.
Baseline lipoprotein profiles were (mean [SD]): total cholesterol, 7.53 (0.75) mmol/L (291 [29] mg/dL); low-density lipoprotein cholesterol (LDL-C), 5.35 (0.78) mmol/L (207 [30] mg/dL); high-density lipoprotein cholesterol (HDL-C), 1.50 (0.41) mmol/L (58 [16] mg/dL); and triglycerides, 1.45 (0.73) mmol/L (127 [64] mg/ dL). Lipoprotein levels were virtually unchanged at the end of both treatment periods (mean difference [95% confidence interval]): total cholesterol, 0.085 (-0.201 to 0.372) mmol/L (3.3 [-7.8 to 14.4] mg/dL), P=.54; LDL-C, 0.001 (-0.242 to 0.245) mmol/L (0.04 [-9.4 to 9.5] mg/dL), P=.99; HDL-C, 0.050 (-0.028 to 0.128) mmol/L (1.9 [-1.1 to 4.9] mg/dL), P=.20; triglycerides, 0.047 (-0.229 to 0.135) mmol/L (4.2 [-20.3 to 12.0]) mg/dL, P=.60. Cholesterol absorption (37.5% [10.5%] vs 38.3% [10.7%0], P=.58), cholesterol synthesis (12.7 [6.5] vs 13.4 [6.6] mg/kg of body weight per day, P=.64), mevalonic acid excretion (192 [66] vs 187 [66] microg/d, P=.78), and changes in the ratio of lathosterol to cholesterol in serum (4.4% [24.3%] vs 10.6% [21.1%], P=.62) were not different in garlic and placebo treatment.
The commercial garlic oil preparation investigated had no influence on serum lipoproteins, cholesterol absorption, or cholesterol synthesis. Garlic therapy for treatment of hypercholesterolemia cannot be recommended on the basis of this study.
含大蒜的药物已被用于治疗高胆固醇血症,尽管其疗效尚未得到普遍证实。关于其对人体胆固醇可能产生影响的作用机制知之甚少。
评估大蒜油的降胆固醇作用,并研究其可能的作用机制。
双盲、随机、安慰剂对照试验。
门诊脂质诊所。
我们调查了25例中度高胆固醇血症患者(平均年龄58岁)。
蒸汽蒸馏大蒜油制剂(每日2次,每次5毫克)与安慰剂各服用12周,洗脱期为4周。
血清脂蛋白浓度、胆固醇吸收及胆固醇合成。
基线脂蛋白谱为(均值[标准差]):总胆固醇7.53(0.75)毫摩尔/升(291[29]毫克/分升);低密度脂蛋白胆固醇(LDL-C)5.35(0.78)毫摩尔/升(207[30]毫克/分升);高密度脂蛋白胆固醇(HDL-C)1.50(0.41)毫摩尔/升(58[16]毫克/分升);甘油三酯1.45(0.73)毫摩尔/升(127[64]毫克/分升)。两个治疗期结束时脂蛋白水平几乎无变化(均值差异[95%置信区间]):总胆固醇0.085(-0.201至0.372)毫摩尔/升(3.3[-7.8至14.4]毫克/分升),P = 0.54;LDL-C 0.001(-0.242至0.245)毫摩尔/升(0.04[-9.4至9.5]毫克/分升),P = 0.99;HDL-C 0.050(-0.028至0.128)毫摩尔/升(1.9[-1.1至4.9]毫克/分升),P = 0.20;甘油三酯0.047(-0.229至0.135)毫摩尔/升(4.2[-20.3至12.0])毫克/分升,P = 0.60。大蒜治疗组与安慰剂治疗组在胆固醇吸收(37.5%[10.5%]对38.3%[10.7%],P = 0.58)、胆固醇合成(12.7[6.5]对13.4[6.6]毫克/千克体重/天,P = 0.64)、甲羟戊酸排泄(192[66]对187[66]微克/天,P = 0.78)以及血清中羊毛甾醇与胆固醇比值的变化(4.4%[24.3%]对10.6%[21.1%],P = 0.62)方面无差异。
所研究的市售大蒜油制剂对血清脂蛋白、胆固醇吸收或胆固醇合成无影响。基于本研究,不推荐使用大蒜疗法治疗高胆固醇血症。